Loading
A phase 2 trial of Disitamab vedotin and Tucatinib in gastric & gastro-oesophageal junction cancer, HER2-positive breast cancer and triple-negative breast cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors is a phase 2 interventional study registered as NCT06157892 by Seagen, a wholly owned subsidiary of Pfizer, with 54 participants enrolled, started 2024-05-20 and due to reach its primary completion in 2029-07-28. Interventions recorded: disitamab vedotin and tucatinib.
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.